An Observational Study of Menopausal Status in Patients With Gynecological Malignancy After Ovariectomy
Study Details
Study Description
Brief Summary
Through long-term dynamic monitoring of gynecologic malignant tumor patients undergoing early menopause after ovaries resection in our center, we explored the changes in menopausal symptoms and bone health status of this population, and studied the effects of platinum combined chemotherapy drugs on menopausal symptoms and bone loss in gynecologic malignant tumor patients. To find the optimal time point and effective regimen for MHT in gynecologic malignancies undergoing surgical menopause, and to provide guidance for osteoporosis screening and prevention strategies in women with gynecologic cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Gynecological malignancies are affecting the health of more and more women in the world, and the age of onset is also gradually younger. For women of reproductive age with gynecologic malignancies, surgery involving bilateral ovariectomy, followed by chemoradiotherapy or anti-estrogen therapy to maintain endocrine therapy, can lead to early menopause, leading to earlier and more severe menopausal syndrome and bone loss. Unlike the management of healthy women with natural menopause, the management of prognosis and quality of life in cancer patients with early menopause resulting from surgery combined with adjuvant therapy is more challenging and specific, and it is critical to identify management options for this complex patient population.
This study aims to conduct long-term dynamic monitoring of patients with gynecologic malignancies undergoing early menopause after ovaries resection in our center, explore the changes in menopausal symptoms and bone health status of this population, and study the effects of platinum combined chemotherapy drugs on menopausal symptoms and bone loss in patients with gynecologic malignancies. To find out the best time point and effective program of menopausal hormone therapy for gynecological malignant tumor patients with surgical menopause, and provide guidance for osteoporosis screening and prevention strategies for women with gynecological cancer.
Study Design
Outcome Measures
Primary Outcome Measures
- Bone mineral density [Bone mineral density was followed up at 1, 2, 3, 6, 9, 12, 24 and 36 months after the operation]
Bone density examination
- KMI [The scale was evaluated at 1, 3, 6 and 12 months after surgery.]
Modified Kupperman Index（0-63score）
- MENQOL [The scale was evaluated at 1, 3, 6 and 12 months after surgery.]
Menopause-Specific Quality of Life（0-174score）
- HADS [The scale was evaluated at 1, 3, 6 and 12 months after surgery.]
Hospital Anxiety and Depression Scale（0-21score）
- IOF [The scale was evaluated at 1, 3, 6 and 12 months after surgery.]
Osteoporosis Risk one-minute Test Scale (Yes or No)
- PSQI [The scale was evaluated at 1, 3, 6 and 12 months after surgery.]
Pittsburgh sleep quality index（0-21score）
Secondary Outcome Measures
- OS [5 year]
OS was defined as the time interval between a patient's diagnosis of gynecologic malignancy and death from any cause or the end of the last follow-up date.
- PFS [5 year]
PFS is defined as the time interval between a patient's diagnosis of gynecological malignancy and the first occurrence of progression of the disease or death from any cause.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Premenopausal women with gynecological malignancies aged 18-55 years old;
-
Tumor types include endometrial cancer, cervical cancer, epithelial ovarian cancer;
-
All patients received standard stage operation and treatment;
-
Patients with bilateral ovaries resection; ⑤Voluntarily participate in this study, willing to sign informed consent, and have long-term follow-up conditions.
Exclusion Criteria:
-
Menopause (women over 40 years of age stop menstruation for 12 months, excluding pregnancy and other diseases that may cause amenorrhea can be clinically diagnosed as menopause); Or AMH < 0.2ng/ml (China Menopause Management and Menopause Hormone Therapy Guidelines 2023 edition); Or FSH> 40 mIU/ml after two checks within one month;
-
Other tumors were combined within 2 years and were still in radiotherapy, chemotherapy or hormone therapy;
-
Diagnosis of immunodeficiency disease or active hepatitis B, C, active tuberculosis; ④Serious organic diseases of the organs, etc., can not cooperate with the study follow-up; ⑤Long-term use of hormonal drugs for rheumatic system diseases, such as glucocorticoids;
-
Patients who have previously received pelvic or abdominal radiotherapy; ⑦ ECOG score ≥3 points; ⑧The patient did not sign informed consent or was unwilling to accept follow-up interviews.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Anhui Provincial Hospital
Investigators
- Study Chair: Ying Zhou, MD, The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Ying Zhou